FDA says the Zepbound shortage is over. Here’s what that means for compounding pharmacies, patients who used off-brand versions - CNBC
- FDA says the Zepbound shortage is over. Here’s what that means for compounding pharmacies, patients who used off-brand versions CNBC
- FDA reaffirms decision to erase Eli Lilly's tirzepatide from shortage list, halting future flow of knockoffs FiercePharma
- Does This News From the FDA Make Eli Lilly a Buy for 2025? The Motley Fool
- FDA says knockoff versions of obesity drug must come off the market East Idaho News
- FDA finalizes decision to end Lilly's GLP-1 shortage, analysts predict Novo will be next Yahoo Finance